Drugs / bivatuzumab mertansine
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02254044 | Oct 2003 → Nov 2004 | squamous cell carcinoma | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT02254031 | Jul 2003 → Jan 2005 | breast neoplasm | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT02254005 | Oct 2002 → Dec 2004 | breast neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02254018 | Sep 2002 → Feb 2005 | head and neck neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bivatuzumab mertansine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02254005 ↗ |
| Known as | BIWA-1-DM1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109288 ↗ |
| Known as | Biwa-4 mertansine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109288 ↗ |
| Route | Intravenous | “Administered intravenously” NCT02254005 ↗ |
| Target | CD44 | “CD44 antigen binding agent” CHEMBL2109288 ↗ |